Los Gatos, California-based Advanced NanoTherapies received the breakthrough nod for the use of the DCB in treating coronary artery disease in vessels less than 3.0mm. The regulatory win comes weeks after two previous breakthrough designations. SirPlux Duo already has breakthrough designation for coronary in-stent restenosis (ISR) and peripheral below-the-knee (BTK) lesions.
Get the full story at our sister site, Drug Delivery Business News.